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hypermethylation of tumour suppressor genes, is a hallmark of cancer.
Information about which methylation events are disease speciﬁc has a
great potential in diagnostics and drug development. The aim of this study
was to investigate the methylation status of the tumour suppressor genes
SHP1, SOCS1 and STAT1, their counterparts SOCS3 and SHP2, as well
as the drug resistance gene MGMT, and their effect on protein expression
and cytotoxic drug sensitivity in glioblastoma cell lines. A further aim was
to investigate the possibility to increase cytotoxic drug sensitivity in the
glioblastoma lines by demethylation treatment.
Methods: To study methylation patterns, bisulﬁte treatment of total
DNA followed by PCR ampliﬁcation and Pyrosequencing® analysis was
employed. Protein expression of total lysates was evaluated by Western
blot analysis. Cytotoxic drug sensitivity was analysed by the ﬂuorometric
microculture cytotoxicity assay. Demethylation was obtained by treatment
with the drug decitabine. Six glioblastoma cell lines were used in the
studies.
Results: MGMT, SHP1 and SOCS1 were methylated at varying levels
in the analyzed gene regions, whereas SHP2, SOCS3 and STAT1 were
not methylated. The observed methylation levels in MGMT and SHP1
were associated with a reduction of protein expression. In addition, a low
degree of methylation and a high protein level of MGMT were related
to a decreased sensitivity to the cytotoxic drugs 5-ﬂuorouracil, 17-AAG,
bortezomib, and picropodophyllin. Finally, it was possible to increase the
sensitivity in the glioblastoma cells lines to several cytotoxic drugs by
demethylation treatment with the drug decitabine.
Conclusions: Epigenetic regulation of MGMT and SHP1 appear to affect
tumor phenotype in glioblastoma. The correlation between a low degree of
methylation of MGMT and SHP1, a high protein level and low sensitivity
to several cytotoxic drugs constitutes a potential predictive marker for
chemotherapy of glioblastoma. Finally, the possibility to increase cytotoxic
drug sensitivity by demethylation treatment points to novel therapeutic
strategies in combination drug therapy of glioblastoma.
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Role of ERK activation in triptolide-induced apoptosis in MDA-MB-231
human breast cancer cells
B.J. Tan1, G.N. Chiu1. 1National University of Singapore, Pharmacy,
Singapore, Singapore
Background: Triptolide (PG490), a compound isolated from Trypterygium
wilfordii, has been shown to have potent activity in a variety of xenograft
tumor models. However, very little is known about the molecular mechanism
by which triptolide acts in cancer cells. Therefore, the aim of this study was
to investigate the role of extracellular signal-regulated protein kinase (ERK),
a member of the mitogen-activated protein kinase family, in triptolide-
induced cell death using the human breast cancer cell line MDA-MB-231.
Materials and Methods: MTT assay was used to determine cell viability
upon treatment with 0−40 ng/mL triptolide. Apoptosis was assessed by
annexin-V/7AAD staining, and caspase 3/7 activity was measured by a
ﬂuorescence-based assay kit. To assess the involvement of ERK and
caspases, phosphorylated ERK and cleaved PARP were probed by western
blot, respectively, as well as by the use of a MEK inhibitor, U0126, and the
pan-caspase inhibitor, Z-VAD-FMK. Expression of phosphorylated eIF2a
was determined by western blot.
Results: Dose-dependent reduction in MDA-MB-231 cell viability was
observed upon a 72-hour exposure to triptolide, with an IC50 value of
1.9 ng/mL. A 3.2-fold increase in annexin-V+/7AAD− cells was observed
when cells were treated with 4 ng/mL triptolide for 48 hours, indicat-
ing induction of apoptosis. Triptolide-induced apoptosis was caspase-
dependent, as supported by signiﬁcant increases in caspase 3/7 activity,
PARP cleavage and cell viability in the presence of caspase inhibitor
Z-VAD-FMK. ERK was activated as early as 2 hour post triptolide treatment,
and remained activated for 48 hours. eIF2a was also activated in a
time-dependent manner in triptolide-treated cells. The concomitant use of
MEK inhibitor, U0126, attenuated triptolide-induced caspase 3/7 activation,
PARP cleavage, and signiﬁcantly increased cell viability from 49% to 98%,
indicating that ERK activation acts upstream of caspase activation.
Conclusion: Our data demonstrated for the ﬁrst time that ERK activation
played an important role in triptolide-induced apoptosis, in contrast to the
general view that ERK activation contributes to cancer cell survival and
proliferation. Furthermore, the sustained activation of ERK, together with
eIF2a activation, suggested a possible link of triptolide-induced apoptosis
to endoplasmic reticulum stress which warrants further characterization.
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Background: ES-285 is a marine compound originating from the mollusc
Spisula polynyma, an edible clam, which is also known as the Stimpson
or Atlantic surf clam. The drug has cytotoxic properties by disrupting actin
ﬁbers and interacting with the ceramide pathway. The agent has a broad
antitumor spectrum in vitro, in vivo and in xenograft models. ES-285 was
subject to 4 parallel Phase I studies in patients (pts) with solid tumors, three
of them reported here, all of them using 3-hour infusions of the compound.
Material and Methods: Pts had advanced malignancies, good perfor-
mance status (ECOG PS 0−2) and adequate organ function. The following
intravenous schedules of ES-285 were tested: (A) 3 h d1 qwk, (B 3 h d1−5
q3wk, and (C) 3 h d1 q3wk.
Results: The dose of ES-285 per administration was ranging from 2–
256mg/m2, depending on the study. 117 pts were entered (25−61 per trial),
their median age was ranging from 52−59 yrs per trial, and there was a
male predominance. The most common tumor types were colorectal, renal
and prostate cancer and melanoma. Pts received a median of 2 cycles
of treatment in all studies, ranging from 1−18 per patient. Less than
15% of treatment cycles were delayed. More than 80% of pts went off
study due to disease progression (83−88%). Only 8.0–13.4% of patients
discontinued due to toxicity. The most common clinical adverse events
were nausea, vomiting, asthenia, pyrexia (all schedules) and injection site
reactions. Anemia, lymphocytopenia and increases of serum liver enzymes
were frequently seen, independent of treatment scheme. Ten dose-limiting
events were observed, mainly consisting of grade 3/4 (CTC version 2.0)
reversible increases in serum ALT, AST and reversible neurotoxicity. Only in
schedule C the maximum tolerated dose (200mg/m2) and recommended
dose (160mg/m2) could be established. Among 117 pts, one melanoma
patient had a non-conﬁrmed partial response (RECIST) and 29 pts had
disease stabilization as best response.
Conclusions: After thorough review of the risk/beneﬁt outcomes of the
Phase I program the clinical studies with ES-285 were discontinued.
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Antiproliferative effects of ﬂuoro-chalcone derivatives in human
melanoma A375 cells and peripheral blood mononuclear cells
K. Henmi1, Y. Hiwatashi1, N. Toyama1, T. Hirano1. 1Tokyo University
of Pharmacy and Life Sciences, Clinical Pharmacology, Tokyo, Japan
Background: At present, no treatment options are available for patients
with advanced melanoma providing either sufﬁcient response rates or a
signiﬁcant prolongation of overall survival. Chalcones are included in fruits
and vegetables, and are suggested to be cancer-preventive. In this study,
we reported the effects of synthetic chalcone derivatives on proliferation of
human melanoma cells and peripheral blood mononuclear cells (PBMCs).
Material and Methods: Twelve synthetic derivatives of methoxy-and/or
ﬂuoro-chalcones were included in this study. To measure the effect of
chalcone derivatives on cells of a human melanoma A375 cell line, we
used the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay
procedures. Effects of chalcones on the proliferation of PBMCs in response
to a T cell mitogen concanavalin A was assessed by [3H] thymidine
incorporation. PBMCs were isolated from seven healthy subjects. Cell cycle
and apoptosis was detected by TUNEL assay and PI staining of the cells,
using ﬂow cytometric analysis.
Results: Four out of the 12 chalcone derivatives: 4-triﬂuoromethyl-
4′-methoxychalcone (CH-1), 4-triﬂuoromethyl-2′-methoxychalcone (CH-3),
3-triﬂuoromethyl-2′, 4′-dimethoxychalcone (CH-4) and 3-triﬂuoromethyl-4′-
methoxychalcone (CH-7) exhibited the strongest antiproliferative effects on
the melanoma cells with IC50values of 9.6, 5.7, 5.8 and 7.2 mM, respectively.
Then, we studied the effects of CH-1, CH-3 and CH-4 on apoptosis and
cell cycle of A375 cells. 10 mM CH-3 induced apoptosis in 0.15, 15.3 and
54.05% of A375 cells at 24, 48, and 72 hr of culture, respectively. Percent
of G2/M phase cells in control wells was 31.2, whereas CH-3and CH-4
caused accumulation of cells in the G2/M phase to be 70.1% and 90.55%,
respectively. On the other hand, CH-1 reduced the G1 phase cells, as
